Expression of gremlin, a bone morphogenetic protein antagonist,is associated with vascular calcification in uraemia

Nephrology Dialysis Transplantation

Volumn 24, Issue 4, 2009, Pages 1121-1129

  Jara, Aquiles ^a   Chacón, Cecilia ^a   Burgos, María Eugenia ^b   Droguett, Alejandra ^b   Valdivieso, Andrés ^a   Ortiz, Mireya ^a   Troncoso, Pablo ^a   Mezzano, Sergio ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

BMP 2; BMP 7 antagonist; CKD; Gremlin; Vascular calcification

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCITRIOL; CYTOKINE RECEPTOR ANTAGONIST; GREMLIN; MESSENGER RNA; OSTEOGENIC PROTEIN 1; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL BIOPSY; BLOOD VESSEL CALCIFICATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; DISSECTION; EPIGASTRIC ARTERY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; STAINING; TUNICA MEDIA; UREMIA;

ANIMALS; AORTIC DISEASES; BONE MORPHOGENETIC PROTEINS; CALCINOSIS; DISEASE MODELS, ANIMAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY TRANSPLANTATION; MALE; RATS; RATS, SPRAGUE-DAWLEY; UREMIA;

EID: 65349196385     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn611     Document Type: Article

References (35)

1. Witteman JC, Kok FJ, van Saase JL et al. Aortic calcification as a predictor of cardiovascular mortality. Lancet 1986; 2: 1120-1122
2. Wilson PWF, Kauppila LI, O'Donnell CJ et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103: 1529-1534
3. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
4. London GM, Marchais SJ, Guerin AP et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens. 2005; 14: 525-531
5. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
6. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
7. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001; 60: 472- 479
8. Shananhan CM, Cary N, Salisbury JR et al. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis. Circulation 1999; 100: 2168-2176
9. Ibels LS, Alfrey AC, Huffer WE et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-796
10. Jono S, McKeeMD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17
11. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567
12. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66
13. Moe S, Duan D, Doehle BP et al. Uremia induces the osteoblast differentiation factor Cbfa-1 in human blood vessels. Kidney Int 2003; 63: 1003-1011
14. Moe S, O-Neill K, Duan D et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61: 638-647
15. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Neprol 2003; 14: 1559-1567
16. Lund RJ, Davies MR, Brown AJ et al. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004; 15: 359-369
17. Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917-928
18. Shao JS, Cheng SL, Pingsterhaus JM et al.Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest2005; 115: 1210-1220
19. Rawadi G, Vayssiere B, Dunn F et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842-1853
20. Zebboudj AF, Imura M, Bostrom K.Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002; 277: 4388-4394
21. Lund RJ, Davies MR, Hruska KA. Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens 2002; 11: 31-36
22. Mezzano S, Droguett A, Burgos ME et al. Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1882-1890
23. WalshDW, Roxburgh SA, McGettigan P et al. Co-regulation ofGremlin and Notch signalling in diabetic nephropathy. Biochim Biophys Acta 2008; 1782: 10-21
24. Carvajal G, Droguett A, Burgos ME et al. Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 2008; 40: 734-739
25. Maciel TT, Melo RS, Schor N et al. Gremlin promotes vascular smooth muscle cell proliferation and migration. J Mol Cell Cardiol2008; 44: 370-379
26. Jara A, Chac'on C, Felsenfeld AJ. How dietary phosphate, renal failure and calcitriol administration affect the serum calcium-phosphate relationship in the rat. Nephrol Dial Transplant 2002; 17: 765-771
27. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804
28. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
29. Simon M, Maresh JG, Harris SE et al. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol 1999; 276: F382-F389
30. Mathew S, Davies M, Lund G et al. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone and the bonevascular links in chronic kidney disease. Eur J Clin Invest 2006; 36(Suppl 2): 43-50
31. Michos O, Panman L, Vintersten K et al. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controllingmetanephric kidney and limb organogenesis. Development2004; 131: 3401-3410
32. Li X, Ying-Yang H, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199: 271-277
33. Bostr̈om K, Watson KE, Horn S et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-1809
34. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114
35. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000; 184: 37-45